

Claims

1. An adeno-associated virus (AAV) vector gene therapy comprising:
a vascular endothelial growth factor (VEGF)C transgene; and
minimal nephrin promoter NPHS1 or podocin promoter NPHS2.
2. An AAV vector gene therapy according to claim 1, wherein the AAV vector is AAV serotype 2/9, LK03 or 3B.
3. An AAV vector gene therapy according to claim 1 or claim 2, wherein the VEGFC transgene comprises a polynucleotide encoding a VEGFC prepropeptide, or an intermediate form of VEGFC or a mature form of VEGFC.
4. An AAV vector gene therapy according to any of claims 1 to 3, wherein the AAV vector additionally comprises a Woodchuck hepatitis post-transcriptional regulatory element (WPRE).
5. An AAV vector gene therapy according to any of claims 1 to 4, wherein the VEGFC transgene is human and/or comprises a hemagglutinin (HA) tag.
6. An AAV vector gene therapy according to any of claims 1 to 5, wherein the AAV vector additionally comprises a Kozak sequence between the promoter and the VEGFC transgene.
7. An AAV vector gene therapy according to any of claims 1 to 6, wherein the AAV vector additionally comprises a polyadenylation signal such as bovine growth hormone (bGH) polyadenylation signal.
8. An AAV vector gene therapy according to any of claims 1 to 7, for use in treating or preventing kidney disease.
9. An AAV vector gene therapy for use according to claim 8, wherein the kidney disease is diabetic kidney disease.
10. An AAV vector gene therapy for use according to claim 9, wherein the diabetic kidney disease is early stage diabetic kidney disease.

11. An AAV vector gene therapy for use according to any of claims 8 to 10, wherein the AAV vector gene therapy is to be administered to a human patient.
12. An AAV vector gene therapy for use according to claim 11, wherein the human patient has type 1 diabetes or type 2 diabetes.
13. An AAV vector gene therapy for use according to any of claims 8 to 12, wherein the AAV vector gene therapy is to be administered systemically.
14. An AAV vector gene therapy for use according to any of claims 8 to 13, wherein the AAV vector gene therapy is to be administered by intravenous injection.
15. An AAV vector gene therapy for use according to any of claims 8 to 14, wherein the AAV vector gene therapy is to be administered by injection into the renal artery.